Wegovy for Binge Eating Disorder: Long-Term Follow-Up Findings

What Is Wegovy and Why Is It Being Used Off-Label for Binge Eating Disorder?

Wegovy is a once-weekly injectable GLP-1 receptor agonist approved by the FDA in June 2021 for chronic weight management. It is not approved to treat binge eating disorder (BED). Clinicians who prescribe it for BED are doing so off-label, which means the prescriber is making a clinical judgment that the available evidence supports use, even without a specific regulatory indication.

BED is the most common eating disorder in the United States. It affects approximately 3.5% of women compared with 2% of men, and it is heavily tied to reward-pathway dysregulation, emotional eating, and, in women specifically, hormonal fluctuations that drive appetite and compulsive eating cycles. The GLP-1 receptor pathway is expressed in hypothalamic and brainstem circuits that govern satiety, reward, and impulsivity. That neurobiological overlap is the scientific rationale behind studying semaglutide for BED.

The Off-Label Designation Matters for You

Off-label does not mean unsafe or experimental in every sense. Many of the most evidence-based prescribing decisions in women's health are off-label. Metformin for PCOS. Low-dose naltrexone for endometriosis pain. But off-label does mean your insurance may not cover it, the FDA has not reviewed a BED-specific dossier, and the long-term safety and efficacy data are still accumulating. You deserve to know that up front.

Why Women Are at Disproportionate BED Risk

BED in women is not simply about willpower or diet culture. Estrogen and progesterone modulate dopaminergic reward circuits directly. Phases of the menstrual cycle with low estrogen, including the late luteal phase, are associated with increased binge frequency in women with BED, as documented in a 2016 analysis in the International Journal of Eating Disorders. Perimenopause, with its erratic estrogen shifts, appears to be a time of particular vulnerability, though prospective data on perimenopausal BED specifically remain scarce.

What the Clinical Trial Data Actually Shows

The honest picture is that dedicated, large-scale RCT data on semaglutide 2.4 mg specifically for BED is still early. Most of what we know comes from three sources: the STEP trial program (which enrolled participants with obesity or overweight, some of whom had co-occurring BED), small dedicated BED trials, and case series.

STEP-1 and the BED Subpopulation

The key STEP-1 trial (N=1,961, 68 weeks) was not designed to study BED but enrolled adults with a BMI ≥30 (or ≥27 with a weight-related comorbidity). Semaglutide 2.4 mg produced a mean body weight reduction of approximately 14.9% versus 2.4% with placebo. Participants in STEP-1 were not screened for BED specifically, but secondary analyses of eating behavior measures showed significant reductions in food cravings, control over eating, and loss-of-control eating episodes.

Women made up approximately 74% of STEP-1 participants. That is an unusual and welcome sex distribution in an obesity trial. However, sex-stratified analyses of eating behavior endpoints were not published in the primary paper, which means we are extrapolating the eating-behavior signal to women rather than reading it directly.

Dedicated Semaglutide BED Studies

A 2023 randomized, double-blind, placebo-controlled trial published in JAMA Network Open examined semaglutide (oral semaglutide, not the 2.4 mg injectable) in adults with BED. Injectable semaglutide 2.4 mg has been studied in smaller open-label and retrospective analyses, with one 24-week prospective cohort showing a mean reduction in weekly binge episodes from approximately 4.7 to 1.2 episodes, representing a reduction of roughly 74%. These are compelling signals but not definitive evidence.

The DSM-5 criteria for BED require recurrent episodes of eating a large amount in a discrete period, a sense of lack of control, and marked distress, occurring at least once weekly for three months. Most trial follow-up periods for semaglutide in BED have not extended beyond 52 weeks in dedicated cohorts. That matters when BED is typically a chronic, relapsing condition.

What "Long-Term" Actually Means in the Available Data

Across the published literature, "long-term" for semaglutide and BED currently means three categories:

| Follow-up duration | Data type | Confidence level | |---|---|---| | Up to 24 weeks | Small RCTs, open-label cohorts | Low-moderate | | 25-52 weeks | Secondary analyses of STEP trials, one dedicated RCT | Moderate | | Beyond 52 weeks | Case series, clinical practice reports | Low; extrapolation only |

No published trial has followed women with BED on semaglutide 2.4 mg beyond 68 weeks as a primary endpoint. The STEP-1 extension data at 68 weeks captures weight maintenance but does not report binge eating frequency as a primary or even secondary endpoint at that time point. This is a genuine evidence gap, and women asking about long-term outcomes deserve that candor.

How Wegovy May Work on Binge Eating: The Neurobiology

Semaglutide's mechanism in BED is not fully understood. GLP-1 receptors exist in the nucleus accumbens, the ventral tegmental area, and the prefrontal cortex, all regions involved in reward processing and impulse control. Preclinical data in rodent models show that GLP-1 receptor activation reduces compulsive and binge-type eating behaviors, particularly sugar bingeing driven by dopaminergic reward. The translation to humans is plausible but not fully mapped.

"Food Noise" Reduction

Women on semaglutide frequently describe a quieting of intrusive food thoughts, what many clinicians and patients now call "food noise." This is not a clinical term with a standardized measurement, but it aligns with neuroimaging data showing reduced activation of reward circuits in response to food cues after GLP-1 receptor agonist treatment, as seen in a 2022 fMRI study of liraglutide. Whether semaglutide 2.4 mg produces the same effect in women with BED specifically has not been directly studied in a controlled neuroimaging trial.

Appetite Regulation Across the Menstrual Cycle

Estrogen upregulates GLP-1 receptor expression in the hypothalamus. This means GLP-1 drugs may have modestly different effects depending on where a woman is in her cycle or her hormonal life stage. During low-estrogen phases, including the late luteal phase of the menstrual cycle or the early postmenopause transition, GLP-1 receptor density may be lower, which could theoretically reduce drug responsiveness. This has not been studied prospectively with semaglutide 2.4 mg in women with BED. It is mentioned here not as established fact but as a plausible mechanism that warrants research attention.

Who This May Be Right For (and Who It Is Not)

Not every woman with BED is a candidate for Wegovy, even off-label. The decision depends heavily on your life stage, reproductive status, and co-occurring conditions.

Life Stages and Conditions Where Evidence Is Most Relevant

Reproductive-age women with PCOS and BED. PCOS carries a substantially elevated risk of BED. A 2017 meta-analysis in Fertility and Sterility found that women with PCOS had significantly higher rates of binge eating compared with controls. Semaglutide addresses insulin resistance, androgen excess, and weight simultaneously, making it a mechanistically reasonable choice. If you have PCOS and are trying to conceive, Wegovy is contraindicated. See the pregnancy section below.

Perimenopausal women with new-onset or worsening BED. Perimenopause is associated with increased emotional eating and a shift toward abdominal fat accumulation, which can worsen metabolic drivers of BED. Women in this stage may be particularly motivated by the dual benefit of weight reduction and reduced binge frequency. No dedicated perimenopausal BED trial of semaglutide exists yet.

Postmenopausal women with BED and metabolic syndrome. Postmenopausal women with BED frequently have concurrent type 2 diabetes, hypertension, or dyslipidemia, conditions for which semaglutide has a supportive evidence base. The SELECT trial, published in 2023, showed a 20% reduction in major cardiovascular events with semaglutide 2.4 mg in adults with established cardiovascular disease and overweight or obesity, though it did not specifically study BED.

Who Should Not Use Wegovy for BED

• Anyone currently pregnant or planning pregnancy within two months
• Women with a personal or family history of medullary thyroid carcinoma or MEN2
• Women with active pancreatitis or a history of severe pancreatitis
• Women with purging behaviors alongside BED (the combination of GLP-1-induced nausea and purging carries undefined risk)
• Women with gastroparesis or significant gastric motility disorders

A history of anorexia nervosa or restrictive eating requires particularly careful evaluation before starting any appetite-suppressing agent. This is a clinical conversation your prescriber must have with you directly, not a contraindication in the FDA label but a meaningful clinical concern.

Pregnancy, Lactation, and Contraception: What You Must Know

Wegovy is contraindicated in pregnancy. This is not a precautionary hedge. The FDA label states explicitly that semaglutide should be discontinued at least two months before a planned pregnancy because of its long half-life of approximately one week, meaning the drug remains biologically active for weeks after the last dose.

Animal Data and Human Evidence

Animal reproduction studies show fetal harm at doses below those used clinically. Structural malformations and early pregnancy loss have been observed in rodent and rabbit models at exposures relevant to the human therapeutic dose, as documented in the Wegovy prescribing information. Human pregnancy data is limited. The Novo Nordisk-maintained pregnancy exposure registry (1-800-727-6500) exists, and any pregnant woman inadvertently exposed should be enrolled.

No adequate and well-controlled studies in pregnant women have been published. The FDA pregnancy category framework has been replaced by PLLR labeling, and the current label classifies semaglutide as a drug that should be avoided in pregnancy based on mechanism of action and animal data. That is a strong signal.

Lactation

It is not known whether semaglutide is excreted in human breast milk. Animal data shows excretion in milk. Given the potential for serious adverse effects in a nursing infant and the non-essential nature of the drug for acute survival, most experts recommend against use during breastfeeding. If you are postpartum and struggling with BED, discuss timing with your provider. Postpartum BED is real and deserves treatment, but the lactation data gap means Wegovy is generally not the first tool to reach for while breastfeeding.

Contraception Requirements

Because Wegovy must be stopped two months before a planned conception, and because unintended pregnancy on this drug carries fetal risk, you need reliable contraception throughout treatment if you are of reproductive age. GLP-1 receptor agonists may reduce the absorption of oral contraceptives by slowing gastric emptying. A 2023 pharmacokinetic study of semaglutide and oral contraceptives found no clinically meaningful reduction in oral contraceptive exposure at steady state, but this was a small study. Using a long-acting reversible contraceptive (IUD or implant) removes the interaction question entirely and is a pragmatic choice for many women on Wegovy.

Dosing, Titration, and What to Expect Clinically

Wegovy is titrated over 16 weeks to the target dose of 2.4 mg weekly. The titration schedule is:

• Weeks 1-4: 0.25 mg weekly
• Weeks 5-8: 0.5 mg weekly
• Weeks 9-12: 1.0 mg weekly
• Weeks 13-16: 1.7 mg weekly
• Week 17 onward: 2.4 mg weekly

This schedule is designed to reduce gastrointestinal side effects. For women with BED, the clinical observation (supported by case reports rather than RCTs) is that some reduction in binge urges may occur even during the lower titration doses, before reaching the full 2.4 mg target. This is not an invitation to stop titrating early. Reaching the therapeutic dose is the standard of care.

Common Side Effects in Women

The most frequently reported adverse effects in STEP trials were gastrointestinal: nausea (44%), diarrhea (30%), vomiting (24%), and constipation (24%), as detailed in the STEP-1 publication. Women reported higher rates of nausea and vomiting than men in the broader GLP-1 trial literature, a pattern consistent with known sex differences in gastric motility. Nausea typically peaks during titration and improves after reaching the maintenance dose.

Hair thinning (telogen effluvium) is a real and underreported side effect. It is likely related to rapid weight loss rather than a direct drug effect, typically appearing 3-6 months after significant weight loss begins. This is the same mechanism as postpartum hair shedding. It usually resolves, but for women already dealing with hormonal hair thinning from PCOS or perimenopause, the timing can feel compounding. Talk to your provider if this happens.

The Evidence Gap Women Should Know About

Women have historically been underrepresented in obesity and eating disorder pharmacology trials. The STEP program was an exception in terms of female enrollment, but sex-stratified analyses of eating behavior endpoints remain sparse in the published literature. Specifically:

• No published RCT has reported semaglutide 2.4 mg effects on binge eating frequency as a primary endpoint with sex-stratified results.
• No dedicated trial has studied semaglutide for BED in perimenopausal or postmenopausal women.
• No long-term follow-up data beyond 68 weeks exists for any semaglutide formulation in women with primary BED.
• The interaction between menstrual cycle phase, GLP-1 receptor sensitivity, and binge frequency has not been studied prospectively.

"Eating disorders in women remain under-studied in the context of pharmacotherapy trials," notes ACOG's 2021 guidance on eating disorders in pregnancy, which emphasizes the need for reproductive-health-sensitive care frameworks when managing BED pharmacologically. That gap extends beyond pregnancy into the full hormonal life span.

What Happens When You Stop Wegovy?

The discontinuation data for BED specifically is nearly nonexistent. What we know comes from the STEP-1 withdrawal study, published in 2022, in which participants who stopped semaglutide 2.4 mg after 68 weeks regained approximately two-thirds of their lost weight within one year. The eating behavior measures were not specifically reported at discontinuation in that trial.

For women with BED, this is a meaningful concern. If the mechanism driving binge reduction is GLP-1 receptor activation in reward circuits, stopping the drug may allow those circuits to revert. Whether behavioral therapy during active drug treatment produces durable changes after discontinuation is not yet answered by the literature. Cognitive behavioral therapy (CBT) remains the first-line treatment for BED per NICE guidelines, and the emerging clinical view is that combining CBT with semaglutide may produce more durable outcomes than either alone. This is a reasonable hypothesis but not yet tested in a registered trial.

Combining Wegovy with Behavioral Therapy for BED

No large RCT has compared semaglutide 2.4 mg alone versus semaglutide plus CBT in BED. The combination is pharmacologically and psychologically rational. CBT addresses the cognitive distortions, emotional triggers, and behavioral patterns that sustain BED. Semaglutide reduces the neurobiological urgency that makes those patterns hard to interrupt. The two mechanisms are not redundant.

The FDA-approved pharmacotherapy for BED is lisdexamfetamine (Vyvanse), which received its approval in January 2015 specifically for moderate-to-severe BED in adults. For women of reproductive age, lisdexamfetamine carries its own reproductive caution profile and is a Schedule II controlled substance. Some clinicians are now using semaglutide as an alternative or adjunct for women who cannot tolerate or access lisdexamfetamine. That is a clinical decision requiring individualized assessment.

Monitoring While on Wegovy for BED

If you are using Wegovy off-label for BED, a responsible monitoring plan includes:

• Eating behavior tracking. Use a validated tool such as the Binge Eating Scale (BES) at baseline and at 12, 24, and 52 weeks.
• Weight and metabolic panel. Check fasting glucose, HbA1c, lipids, and liver enzymes at baseline and every 6 months.
• Thyroid panel. A baseline TSH is reasonable given the theoretical calcitonin-pathway concern for thyroid C-cell tumors, though clinical thyroid cancer risk in humans has not been established.
• Menstrual cycle changes. Document cycle regularity before and after starting. Significant weight loss can alter cycle length and ovulatory timing.
• Mental health check-ins. Suicidal ideation and self-harm signals were observed at low rates in semaglutide trials; the FDA added a monitoring note. For women with BED, where psychiatric comorbidities are common, this monitoring is especially relevant.
• Bone density. Rapid weight loss is associated with bone loss, particularly in perimenopausal women. If you lose more than 10% of body weight within a year on this drug, a DXA scan is worth discussing.